| 摘要: |
| 肝细胞癌（HCC）是常见的恶性肿瘤，手术治疗为其首选治疗方法，但仅适用于少数患者，且术后复发率较高。因此，开发有效的术后辅助治疗手段以降低复发率、提高患者生存率至关重要。近年来，局部治疗和系统治疗（如肝动脉灌注化疗、放疗、靶向及免疫治疗等）在晚期HCC治疗中显示出良好的抗肿瘤效果，这为HCC的术后辅助治疗提供了更多策略。本文概述了现有HCC术后辅助治疗方法及研究现状。 |
| 关键词: 肝细胞癌 肿瘤复发 术后辅助治疗 免疫治疗 靶向治疗 |
| DOI：10.16781/j.CN31-2187/R.20240072 |
| 投稿时间：2024-01-25修订日期：2024-05-03 |
| 基金项目:国家重点研发计划（2022YFC2503700），上海市重中之重-肝胆临床研究中心项目（2023ZZ02005）. |
|
| Postoperative adjuvant therapies for hepatocellular carcinoma: research progress |
| ZHANG Haijing1,ZHU Hongfei2,CHENG Yuqiang2,CHENG Shuqun1,2* |
(1. Guangdong Pharmaceutical University, Guangzhou 510000, Guangdong, China;
2. Department of Hepatic Surgery (Ⅵ), The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| Hepatocellular carcinoma (HCC) is a common malignant tumor. Surgical treatment is the first choice, but it is only applicable to a few patients, and the recurrence rate is high. Therefore, it is crucial to develop effective postoperative adjuvant therapies to reduce the recurrence rate and improve patient survival. In recent years, local and systemic therapies (e.g., hepatic artery perfusion chemotherapy, radiotherapy, targeted therapy, and immunotherapy) have shown promising anti-tumor effects in the treatment of advanced HCC, which provides more strategies for postoperative adjuvant treatment of HCC. This article summarizes the current postoperative adjuvant therapies for HCC and the research status. |
| Key words: hepatocellular carcinoma tumor recurrence postoperative adjuvant therapy immunotherapy targeted therapy |
